ATE237311T1 - Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung - Google Patents

Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Info

Publication number: ATE237311T1
Authority: AT; Austria
Prior art keywords: vinca alkaloid; tumor targeting; vesicles; increased effectiveness; liposome
Prior art date: 1994-06-27

Application number

AT95926111T

Other languages

English (en)

Inventor

Eric Forssen

Gerry W Cox

Denniss Hair

Original Assignee

Nexstar Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-27

Filing date

1995-06-27

Publication date

2003-05-15

1995-06-27 Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237311T1 publication Critical patent/ATE237311T1/de

Links

229940122803 Vinca alkaloid Drugs 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
230000008685 targeting Effects 0.000 title abstract 2
239000002502 liposome Substances 0.000 abstract 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 abstract 1
150000001450 anions Chemical class 0.000 abstract 1
239000008346 aqueous phase Substances 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002691 unilamellar liposome Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

AT95926111T 1994-06-27 1995-06-27 Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung ATE237311T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26605994A	1994-06-27	1994-06-27
US08/389,663 US5714163A (en)	1994-06-27	1995-02-16	Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
PCT/US1995/008037 WO1996000057A1 (en)	1994-06-27	1995-06-27	Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties

Publications (1)

Publication Number	Publication Date
ATE237311T1 true ATE237311T1 (de)	2003-05-15

Family

ID=26951608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95926111T ATE237311T1 (de)	1994-06-27	1995-06-27	Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung

Country Status (9)

Country	Link
US (2)	US5714163A (de)
EP (1)	EP0734252B1 (de)
AT (1)	ATE237311T1 (de)
AU (1)	AU684209B2 (de)
CA (1)	CA2191077C (de)
DE (1)	DE69530368T2 (de)
DK (1)	DK0734252T3 (de)
ES (1)	ES2197919T3 (de)
WO (1)	WO1996000057A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714163A (en) *	1994-06-27	1998-02-03	Nexstar Pharmaceuticals, Inc.	Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5876728A (en) *	1995-02-15	1999-03-02	Howard David Kass	Natural composition extracted from plants used in the treatment of cancer
US5800833A (en) *	1995-02-27	1998-09-01	University Of British Columbia	Method for loading lipid vesicles
US6740335B1 (en) *	1997-09-16	2004-05-25	Osi Pharmaceuticals, Inc.	Liposomal camptothecin formulations
US6120800A (en) *	1997-09-25	2000-09-19	Nexstar Pharmaceuticals, Inc.	Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6723338B1 (en) *	1999-04-01	2004-04-20	Inex Pharmaceuticals Corporation	Compositions and methods for treating lymphoma
US7311924B2 (en)	1999-04-01	2007-12-25	Hana Biosciences, Inc.	Compositions and methods for treating cancer
WO2000059473A1 (en)	1999-04-01	2000-10-12	Inex Pharmaceuticals Corp.	Compositions and methods for treating lymphoma
US7244450B2 (en) *	1999-04-01	2007-07-17	Inex Pharmaceuticals Corporation	Compositions and methods for treating lymphoma
EP1685843A1 (de) *	1999-06-30	2006-08-02	Ruey J. Dr. Yu	Oligosaccharidealdonsäure und ihre topische Verabreichung
US7452545B2 (en) *	2001-11-13	2008-11-18	Yu Ruey J	Oligosaccharide aldonic acids and their topical use
US6335023B1 (en)	1999-06-30	2002-01-01	Ruey J. Yu	Oligosaccharide aldonic acids and their topical use
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2002244247B2 (en)	2001-03-01	2007-12-13	Harbor Biosciences, Inc.	Use of certain steroids for treatment of blood cell deficiencies
US20030082228A1 (en) *	2001-05-09	2003-05-01	Inex Pharmaceuticals Corporation	Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
US8980310B2 (en) *	2002-12-31	2015-03-17	Bharat Serums and Vaccines, Ltd.	Non-pegylated long-circulating liposomes
EP2471536A1 (de)	2004-09-29	2012-07-04	Harbor BioSciences, Inc.	Steroidanaloga sowie charakterisierungs- und behandlungsverfahren
US20070026061A1 (en) *	2005-05-25	2007-02-01	Nahid Ali	Liposomal formulation and use thereof
EP1932517A3 (de) *	2006-12-11	2008-07-16	Universiteit Utrecht Holding B.V.	Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
PL387296A1 (pl) *	2009-02-17	2010-08-30	Instytut Farmaceutyczny	Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
US11458199B2 (en) *	2012-08-21	2022-10-04	Opko Pharmaceuticals, Llc	Liposome formulations
MX2015005992A (es)	2012-11-20	2016-03-07	Spectrum Pharmaceuticals Inc	Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
TWI678213B (zh)	2015-07-22	2019-12-01	美商史倍壯製藥公司	用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
US11331272B2 (en) *	2017-01-18	2022-05-17	Temasek Life Sciences Laboratory Limited	Hyperstabilized liposomes increase targeting of mitotic cells
US10836788B2 (en)	2019-02-05	2020-11-17	SD Chem, Inc.	Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1270198C (en) *	1984-08-08	1990-06-12	Marcel B Bally	ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5019369A (en) *	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
IE58981B1 (en) *	1985-10-15	1993-12-15	Vestar Inc	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0714865B2 (ja) *	1986-10-28	1995-02-22	武田薬品工業株式会社	リポソ−ム製剤およびその製造法
AU604288B2 (en) *	1987-01-26	1990-12-13	Vestar, Inc.	Phospholipid delivery vehicle for aqueous-insoluble active ingredients
IL91664A (en) *	1988-09-28	1993-05-13	Yissum Res Dev Co	Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5032401A (en) *	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
JP2880800B2 (ja) *	1989-06-22	1999-04-12	ネクスター・フアーマシユーテイカルズ・インコーポレイテツド	カプセル化方法
US5322862A (en) *	1990-05-22	1994-06-21	Nippon Kayaku Kabushiki Kaisha	Resin molding composition for preventing gnawing damage by animals
JPH06511470A (ja) *	1991-07-03	1994-12-22	ネクスター・フアーマシユーテイカルズ・インコーポレイテツド	薬剤を含むリポソームの調製における充填技術
EP0661044A1 (de) *	1991-07-03	1995-07-05	NeXstar Pharmaceuticals, Inc.	Arzneistoff enthaltende Liposomen
US5714163A (en) *	1994-06-27	1998-02-03	Nexstar Pharmaceuticals, Inc.	Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties

1995
- 1995-02-16 US US08/389,663 patent/US5714163A/en not_active Expired - Lifetime
- 1995-06-27 ES ES95926111T patent/ES2197919T3/es not_active Expired - Lifetime
- 1995-06-27 AT AT95926111T patent/ATE237311T1/de active
- 1995-06-27 EP EP95926111A patent/EP0734252B1/de not_active Expired - Lifetime
- 1995-06-27 AU AU29984/95A patent/AU684209B2/en not_active Expired
- 1995-06-27 DK DK95926111T patent/DK0734252T3/da active
- 1995-06-27 CA CA002191077A patent/CA2191077C/en not_active Expired - Lifetime
- 1995-06-27 DE DE69530368T patent/DE69530368T2/de not_active Expired - Lifetime
- 1995-06-27 WO PCT/US1995/008037 patent/WO1996000057A1/en not_active Ceased
1997
- 1997-09-25 US US08/937,935 patent/US5888537A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2998495A (en)	1996-01-19
DE69530368T2 (de)	2003-12-18
CA2191077A1 (en)	1996-01-04
US5714163A (en)	1998-02-03
DK0734252T3 (da)	2003-07-21
EP0734252B1 (de)	2003-04-16
US5888537A (en)	1999-03-30
CA2191077C (en)	2008-02-05
WO1996000057A1 (en)	1996-01-04
DE69530368D1 (de)	2003-05-22
AU684209B2 (en)	1997-12-04
EP0734252A1 (de)	1996-10-02
ES2197919T3 (es)	2004-01-16

Legal Events

Date

Code

Title

Description

2003-11-15

UEP

Publication of translation of european patent specification

Ref document number: 0734252

Country of ref document: EP

Publication	Publication Date	Title
ATE237311T1 (de)	2003-05-15	Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
DE69923181D1 (de)	2005-02-17	Temperatursensitive liposomale formulierung
AU2709495A (en)	1996-01-15	Sphingosomes for enhanced drug delivery
AU3922193A (en)	1993-10-21	Liposome encapsulated taxol and a method of using the same
CA2196780A1 (en)	1996-02-15	A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
GR1000074B (el)	1990-10-31	Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
NZ503568A (en)	2001-03-30	Biphasic lipid vesicle composition for transdermal administration of an immunogen
AU4711296A (en)	1996-09-18	Method for loading lipid vesicles
WO2001039744A3 (en)	2002-01-24	Radiation sensitive liposomes
CA1262334C (en)	1989-10-17	STEROID LIPOSOMES
EP0727982A4 (de)	1998-07-29	Propylenglykolstearat-vesikel
AU4221400A (en)	2000-10-23	Fusogenic lipids and vesicles
AU7343894A (en)	1995-02-28	Biphasic multilamellar lipid vesicles
DE69513878D1 (de)	2000-01-20	Topisches kosmetisches oder pharmazeutisches Mittel
AU3762595A (en)	1996-05-06	Ether lipid liposomes and their therapeutic use
ES2134846T3 (es)	1999-10-16	Formulacion de antibiotico y uso para infecciones resistentes a farmacos.
ATE260643T1 (de)	2004-03-15	System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform
ATE226843T1 (de)	2002-11-15	Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
CA2175471A1 (en)	1995-05-18	Sucrose distearate lipid vesicles
CA2326348A1 (en)	1999-10-07	Liposomal bupivacaine compositions and methods of preparation
AU1776801A (en)	2001-06-04	Modular targeted liposomal delivery system
WO2003018018A3 (en)	2003-05-01	Vinorelbine compositions and methods of use
ATE112679T1 (de)	1994-10-15	Wässrige bereitung von liposomenzusammensetzungen.
DK1360958T3 (da)	2007-01-29	Liposomformulering af clobetasolpropionat
DE69520231D1 (de)	2001-04-05	Liposomzubereitungen enthaltend hybrid-interferon